

**Klinik für Psychiatrie und Psychotherapie
Universitätsmedizin
der Johannes Gutenberg-Universität Mainz (KöR)
(Direktor: Prof. Dr. Klaus Lieb)**

VERÖFFENTLICHUNGEN

2011

- 1 **Bernow N, Kruck B, Pfeifer P, Lieb K, Tüscher O, Fehr C.** Impulsiveness and Venturesomeness in German Smokers. NICOTINE & TOBACCO RESEARCH. 2011; 13 (8): 714-721
- 2 **Bernow N, Yakushev I,** Landvogt C, Buchholz HG, Smolka MN, Bartenstein P, **Lieb K,** Gründer G, Vernaleken I, Schreckenberger M, **Fehr C.** Dopamine D2/D3 receptor availability and venturesomeness. PSYCHIATRY RESEARCH-NEUROIMAGING. 2011; 193 (2): 80-84
- 3 Bohus M, **Lieb K.** Borderline-Persönlichkeitsstörungen (ICD-10 F6). Beitrag in: Therapie psychischer Erkrankungen. Herausgeber: Voderholzer, Hohagen, Urban & Fischer München, 6. Aufl. 2011, S.302-311
- 4 Breitling LP, Müller H, Illig T, Rujescu D, Winterer G, **Dahmen N,** Nitz B, Raum E, Rothenbacher D, Brenner H. Dopamine-related genes and spontaneous smoking cessation in ever-heavy smokers. PHARMACOGENOMICS. 2011; 12(8): 1099-1106
- 5 Brinkmeyer J, **Mobascher A,** Musso F, Schmitz M, Wagner M, Frommann I, Gründer G, Spreckelmeyer KN, Wienker T, Diaz-Lacava A, Holler D, **Dahmen N,** Thürauf N, Clepce M, Kiefer F, de Millas W, Gallinat J, Winterer G. P50 sensory gating and smoking in the general population. ADDICTION BIOLOGY. 2011; 16(3): 485-498
- 6 **Brünen S,** Vincent PD, Baumann P, **Hiemke C,** Havemann-Reinecke U. Therapeutic Drug Monitoring for Drugs Used in the Treatment of Substance-Related Disorders: Literature Review Using a Therapeutic Drug Monitoring Appropriateness Rating Scale THERAPEUTIC DRUG MONITORING. 2011; 33 (5): 561-572
- 7 Conca A, Baumann P, **Hiemke C.** Therapeutic Drug Monitoring in Psychiatry. PHARMACOPSYCHIATRY. 2011; 44(6): 193-194
- 8 Conca A, Schmidt E, Pastore M, **Hiemke C,** Duffy D, Giupponi G. Therapeutic Drug Monitoring in Italian Psychiatry. PHARMACOPSYCHIATRY. 2011; 44 (6): 259-262
- 9 Doering S, **Stoffers J, Lieb K.** Psychotherapieforschungsanalyse. Beitrag in: Handbuch der Borderline-Störungen. Herausgeber: Dulz B, Herpertz SC, Kernberg OF, Sachsse U, Schattauer 2. Aufl. 2011, S.836-854
- 10 **Dreimüller N, Tadic A, Lieb K.** Welches ist das Antidepressivum der ersten Wahl? InFo Neurologie & Psychiatrie. 2011; 13 (1): 25-29
- 11 Eggart V, **Hiemke C,** Zernig G. "There is no dose-response relationship in psychopharmacotherapy" vs "pharmacotherapy in psychiatry is based on ligand-receptor interaction": a unifying hypothesis and the need for plasma concentration based clinical trials. PSYCHOPHARMACOLOGY. 2011; 217(2): 297-300

- 12 **Engel A, Dahmen N.** Appetite and Obesity. Beitrag in: Narcolepsy. Herausgeber: Baumann, CR, Springer New York, 2011, S.227-237
- 13 **Engel A, Helfrich J, Manderscheid N, Musholt PB, Forst T, Pfützner A, Dahmen N.** Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index? NEUROPSYCHIATRIC DISEASE AND TREATMENT. 2011; 7: 351-356
- 14 **Fellgiebel A, Keller I, Martus P, Ropele S, Yakushev I, Böttcher T, Fazekas F, Rolfs A.** Basilar Artery Diameter Is a Potential Screening Tool for Fabry Disease in Young Stroke Patients. CEREBROVASCULAR DISEASES. 2011; 31(3): 294-299
- 15 **Fellgiebel A, Yakushev I.** Diffusion Tensor Imaging of the Hippocampus in MCI and Early Alzheimer's Disease. JOURNAL OF ALZHEIMERS DISEASE. 2011; 26 (Suppl.3): 257-262
- 16 **Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt E, Lieb K.** Non-Medical Use of Prescription Stimulants and Illicit Use of Stimulants for Cognitive Enhancement in Pupils and Students in Germany. PHARMACOPSYCHIATRY. 2011; 44 (2): 60-66
- 17 **Franke AG, Christmann M, Bonertz C, Fellgiebel A, Huss M, Lieb K.** Use of Coffee, Caffeinated Drinks and Caffeine Tablets for Cognitive Enhancement in Pupils and Students in Germany. PHARMACOPSYCHIATRY. 2011; 44 (7): 331-338
- 18 **Franke AG, Hildt E, Lieb K.** Muster des Missbrauchs von (Psycho-) Stimulanzien zum pharmakologischen Neuroenhancement bei Studierenden. Patterns of Misuse of Stimulants for Pharmacological Neuroenhancement in Students. SUCHTTHERAPIE. 2011; 12 (4): 167-172
- 19 **Franke AG, Konrad A, Lieb K, Huss M.** Psychostimulantien und Nicht-Stimulantien in der heutigen und zukünftigen ADHS-Therapie. Fortschr Neurol Psychiatr. 2012; 80(3): 130-40
- 20 Frauenknecht S, **Lieb K.** Last minute Psychiatrie. Herausgeber: Frauenknecht S, Lieb K., Urban & Fischer in Elsevier 2011, 240 S
- 21 Freyer T, Klöppel S, **Tüscher O**, Kordon A, Zurowski B, Kuelz AK, Speck O, Glauche V, Voderholzer U. Frontostriatal activation in patients with obsessive-compulsive disorder before and after cognitive behavioral therapy. PSYCHOLOGICAL MEDICINE. 2011; 41(1): 207-216
- 22 Gründer G, **Hiemke C**, Paulzen M, Veselinovic T, Vernaleken I. Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging. PHARMACOPSYCHIATRY. 2011; 44 (6): 236-248
- 23 Haenisch B, **Hiemke C**, Bonisch H. Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters. PSYCHOPHARMACOLOGY. 2011; 217(2): 289-295

- 24 **Haji E, Tadic A, Wagner S, Dragicevic A**, Müller MJ, Boland K, Rao ML, Fric M, Laux G, **Hiemke C**. Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major Depression. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2011; 31 (3): 281-286
- 25 **Helmreich I, Wagner S**, Mergl R, Allgaier AK, Hautzinger M, Henkel V, Hegerl U, **Tadic A**. The Inventory of Depressive Symptomatology (IDS-C-28) is more sensitive to changes in depressive symptomatology than the Hamilton Depression Rating Scale (HAMD(17)) in patients with mild major, minor or subsyndromal depression. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE. 2011; 261 (5): 357-367
- 26 Hemmelmann M, **Knoth C, Schmitt U**, Allmeroth M, Moderegger D, Barz M, Koynov K, **Hiemke C**, Rösch F, Zentel R. HPMa Based Amphiphilic Copolymers Mediate Central Nervous Effects of Domperidone. MACROMOLECULAR RAPID COMMUNICATIONS. 2011; 32 (9-10): 712-717
- 27 **Hiemke C**, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Sirot EJ, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgl R, Zernig G. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. PHARMACOPSYCHIATRY. 2011; 44 (6): 195-235
- 28 Hildt E, **Franke AG, Lieb K**. Pharmacological Neuroenhancement Information and Acceptance among Students. NERVENHEILKUNDE. 2011; 30(10): 833-837
- 29 Jacob GA, Arendt J, Kolley L, Scheel CN, Bader K, **Lieb K**, Arntz A, **Tüscher O**. Comparison of different strategies to decrease negative affect and increase positive affect in women with borderline personality disorder. BEHAVIOUR RESEARCH AND THERAPY. 2011; 49 (1): 68-73
- 30 Jacob GA, Arntz A, Domes G, **Reiss N**, Siep N. Positive erotic picture stimuli for emotion research in heterosexual females. PSYCHIATRY RESEARCH. 2011; 190 (2-3): 348-351
- 31 Jacob GA, **Lieb K**, Arntz A. Schematherapie bei Borderline-Persönlichkeitsstörung. Beitrag in: Handbuch der Borderline-Störungen. Herausgeber: Dulz B, Herpertz SC, Kernberg OF, Sachsse U, Schattauer 2. Aufl. 2011, S.640-651
- 32 Jacob GA, **Lieb K**. Schema Therapy Quo Vadis? ZEITSCHRIFT FÜR PSYCHIATRIE PSYCHOLOGIE UND PSYCHOTHERAPIE. 2011; 59(3): 177-178
- 33 Jacob GA, **Lieb K**. Schematherapie bei Borderline-Persönlichkeitsstörungen. In: Roediger E, Jacob G (Hrsg) Fortschritte der Schematherapie. Hogrefe Göttingen 2011, S 122-130
- 34 Joos A, Hartmann A, Glauche V, Perlov E, Unterbrink T, Saum B, **Tüscher O**, van Elst LT, Zeeck A. Grey Matter Deficit in Long-Term Recovered Anorexia Nervosa Patients. EUROPEAN EATING DISORDERS REVIEW. 2011; 19 (1): 59-63

- 35 Joos AAB, Saum B, van Elst LT, Perlov E, Glauche V, Hartmann A, Freyer T, **Tüscher O**, Zeeck A. Amygdala hyperreactivity in restrictive anorexia nervosa PSYCHIATRY RESEARCH-NEUROIMAGING. 2011; 191 (3): 189-195
- 36 Joos AAB, Saum B, Zeeck A, Perlov E, Glauche V, Hartmann A, Freyer T, Sandholz A, Unterbrink T, van Elst LT, **Tüscher O**. Frontocingular Dysfunction in Bulimia Nervosa when Confronted with Disease-specific Stimuli. EUROPEAN EATING DISORDERS REVIEW. 2011; 19 (5): 447-453
- 37 Junginger T, Bohl JRE, **Fellgiebel A, Lieb K**. Kunst des Alterns. Herausgeber: Junginger T, Bohl JRE, Fellgiebel A, Lieb K, Kovac, J 1. Aufl. 2011, 176 S Seiten
- 38 Karlsson L, **Hiemke C**, Carlsson B, Josefsson M, Ahlner J, Bengtsson F, **Schmitt U**, Kugelberg FC. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. PSYCHOPHARMACOLOGY. 2011; 215 (2): 367-377
- 39 Koopmann A, Dinter C, Grosshans M, von der Goltz C, Hentschel R, **Dahmen N**, Gallinat J, Wagner M, Gründer G, Thürauf N, Wienker T, Brinkmeyer J, **Mobascher A**, Spreckelmeyer KN, Clepce M, de Millas W, Wiedemann K, Winterer G, Kiefer F. Psychological and hormonal features of smokers at risk to gain weight after smoking cessation - Results of a multicenter study HORMONES AND BEHAVIOR. 2011; 60 (1): 58-64
- 40 Lenz M, Musso M, Linke Y, **Tüscher O**, Timmer J. Joint EEG/fMRI state space model for the detection of directed interactions in human brains-a simulation study. PHYSIOLOGICAL MEASUREMENT. 2011; 32(11): 1725-1736
- 41 Leppä E, Linden AM, Rabe H, Vekovischeva OY, Wulff P, **Lüddens H**, Wisden W, Korpi ER. Actions of two GABA(A) receptor benzodiazepine-site ligands that are mediated via non-gamma 2-dependent modulation. EUROPEAN JOURNAL OF PHARMACOLOGY. 2011; 666 (1-3): 111-121
- 42 **Lieb K, Franke AG**. Möglichkeiten und Grenzen des pharmakologischen Neuroenhancements. Beitrag in: Evolution. Theorie, Formen und Konsequenzen eines Paradigmas in Natur, Technik und Kultur. Herausgeber: Gerhardt V, Lucas K, Stock G, Akademie Verlag 2011, S.255-266
- 43 **Lieb K**, Klemperer D, Ludwig WD. Interessenkonflikte in der Medizin. Hintergründe und Lösungsmöglichkeiten. Herausgeber: Lieb K, Klemperer D, Ludwig WD, Springer Berlin, 1. Aufl. 2011, 300 S Seiten
- 44 **Lieb K, Limbach U**, Klemperer D. Offenlegung von Interessenkonflikten. Beitrag in: Interessenkonflikte in der Medizin. Hintergründe und Lösungsmöglichkeiten. Herausgeber: Lieb K, Klemperer D, Ludwig WD, Springer 1. Aufl. 2011, S.62-78
- 45 **Lieb K**. Neuroenhancement mit Medikamenten. Beitrag in: Rückenwind. Was Studis gegen Stress tun können. In: Rückenwind. Herausgeber: Duriska M, Ebner-Priemer U, Stolle M. Kraft Ettligen, 2011, S.94-97

- 46 Liepert J, Hassa T, **Tüscher O**, Schmidt R. Motor excitability during movement imagination and movement observation in psychogenic lower limb paresis. JOURNAL OF PSYCHOSOMATIC RESEARCH. 2011; 70(1): 59-65
- 47 Linden AM, **Schmitt U**, Leppä E, Wulff P, Wisden W, **Lüddens H**, Korpi ER. Ro 15-4513 Antagonizes Alcohol-Induced Sedation in Mice Through $\alpha\beta 2$ -type GABA(A) Receptors. Frontiers in Neuroscience. 2011; 5 (3): 1-12
- 48 Lindenberg A, Brinkmeyer J, **Dahmen N**, Gallinat J, de Millas W, **Mobascher A**, Wagner M, Schulze-Rauschenbach S, Gründer G, Spreckelmeyer KN, Clepce M, Thürauf N, von der Goltz C, Kiefer F, Steffens M, Holler D, Diaz-Lacava A, Wienker T, Winterer G. The German multi-centre study on smoking-related behavior-description of a population-based case-control study. ADDICTION BIOLOGY. 2011; 16(4): 638-653
- 49 Paunel-Görgülü AN, **Franke AG**, Paulsen FP, Dünker N. Trefoil factor family peptide 2 acts pro-proliferative and pro-apoptotic in the murine retina. HISTOCHEMISTRY AND CELL BIOLOGY. 2011; 135 (5): 461-473
- 50 Preuss UW, Ridinger M, Rujescu D, Samochowiec J, **Fehr C**, Wurst FM, Koller G, Bondy B, Wodarz N, Debniak T, Grzywacz A, Soyka M, Zill P. Association of ADH4 genetic variants with alcohol dependence risk and related phenotypes: results from a larger multicenter association study. ADDICTION BIOLOGY. 2011; 16 (2): 323-333
- 51 Rat D, **Schmitt U**, Tippmann F, Dewachter I, Theunis C, Wiczczak E, Postina R, van Leuven F, **Fahrenholz F**, Kojro E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB JOURNAL. 2011; 25(9): 3208-3218
- 52 **Reiss N, Mobascher A, Lieb K**. Schematherapie in Gruppen für Patienten mit Borderline-Persönlichkeitsstörung. Schema Therapy in Groups for Patients with Borderline Personality Disorder. ZEITSCHRIFT FÜR PSYCHIATRIE PSYCHOLOGIE UND PSYCHOTHERAPIE. 2011; 59 (3): 187-194
- 53 **Reiss N, Vogel F**. Stationäre Schematherapie bei Borderline-Persönlichkeitsstörungen. In: Roediger E, Jacob G (Hrsg) Fortschritte der Schematherapie. Hogrefe Göttingen 2011, S 217-226
- 54 **Schermuly I, Müller MJ, Müller KM, Albrecht J, Keller I, Yakushev I, Beck M, Fellgiebel A**. Neuropsychiatric symptoms and brain structural alterations in Fabry disease. EUROPEAN JOURNAL OF NEUROLOGY. 2011; 18 (2): 347-353
- 55 **Schermuly I, Wolf D, Lieb K, Stoeter P, Fellgiebel A**. State dependent posterior hippocampal volume increases in patients with major depressive disorder. JOURNAL OF AFFECTIVE DISORDERS. 2011; 135 (1-3): 405-409
- 56 **Schmitt U, Leed DE, Herth MM, Piel M, Buchholz HG, Rösch F, Hiemke C, Lüddens H, Debus F**. P-Glycoprotein Influence on the Brain Uptake of a 5-HT_{2A} Ligand: [F-18]MH.MZ. NEUROPSYCHOBIOLOGY. 2011; 63 (3): 183-190

- 57 Schott G, **Lieb K**, Ludwig WD. Auswirkungen von Interessenkonflikten auf Arzneimittelstudien. Beitrag in: Interessenkonflikte in der Medizin. Hintergründe und Lösungsmöglichkeiten. Herausgeber: Lieb K, Klemperer D, Ludwig WD, Springer 2011, S.266-277
- 58 Schumann G, Coin LJ, Lourdasamy A, Charoen P, Berger KH, Stacey D, Desrivieres S, Aliev FA, Khan AA, Amin N, Aulchenko YS, Bakalkin G, Bakker SJ, Balkau B, Beulens JW, Bilbao A, de Boer RA, Beury D, Bots ML, Breetvelt EJ, Cauchi S, Cavalcanti-Proenca C, Chambers JC, Clarke TK, **Dahmen N**, de Geus EJ, Dick D, Ducci F, Easton A, Edenberg HJ, Esk T, Fernandez-Medarde A, Foroud T, Freimer NB, Girault JA, Grobbee DE, Guarrera S, Gudbjartsson DF, Hartikainen AL, Heath AC, Hesselbrock V, Hofman A, Hottenga JJ, Isohanni MK, Kaprio J, Khaw KT, Kuehnel B, Laitinen J, Lobbens S, Luan JA, Mangino M, Maroteaux M, Matullo G, McCarthy MI, Mueller C, Navis G, Numans ME, Nunez A, Nyholt DR, Onland-Moret CN, Oostra BA, O'Reilly PF, Palkovits M, Penninx BW, Polidoro S, Pouta A, Prokopenko I, Ricceri F, Santos E, Smit JH, Soranzo N, Song K, Sovio U, Stumvoll M, Surakk I, Thorgeirsson TE, Thorsteinsdottir U, Troakes C, Tyrfingsson T, Tonjes A, Uitterwaal CS, Uitterlinden AG, van der Harst P, van der Schouw YT, Staehlin O, Vogelzangs N, Vollenweider P, Waeber G, Wareham NJ, Waterworth DM, Whitfield JB, Wichmann EH, Willemsen G, Witteman JC, Yuan X, Zhai GJ, Zhao JH, Zhang WH, Martin NG, Metspalu A, Doering A, Scott J, Spector TD, Loos RJ, Boomsma DI, Mooser V, Peltonen L, Stefansson K, van Duijn CM, Vineis P, Sommer WH, Kooner JS, Spanagel R, Heberlein UA, Jarvelin MR, Elliott P. Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumption. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2011; 108 (17): 7119-7124
- 59 Seibold P, Hein R, Schmezer P, Hall P, Liu JJ, **Dahmen N**, Flesch-Janys D, Popanda O, Chang-Claude J. Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk. INTERNATIONAL JOURNAL OF CANCER. 2011; 129 (6): 1467-1476
- 60 **Stieffenhofer V, Saglam H**, Schmidtman I, Silver H, **Hiemke C, Konrad A**. Clozapine Plasma Level Monitoring for Prediction of Rehospitalization Schizophrenic Outpatients. PHARMACOPSYCHIATRY. 2011; 44 (2): 55-59
- 61 **Stoffers J**, Jacob G, **Lieb K**. Störungsspezifische Psychotherapie der Borderline-Persönlichkeitsstörung. In: Psychiatrie, Psychosomatik und Psychotherapie. Herausgeber: Möller, Laux, Kapfhammer, Springer Berlin, 4. Aufl. Bd. 1, 2011, S.908-919
- 62 **Stoffers J, Lieb K**. Pharmakotherapie der Borderline-Persönlichkeitsstörung. Beitrag in: Handbuch der Borderline-Störungen. Herausgeber: Dulz B, Herpertz SC, Kernberg OF, Sachsse U, Schattauer 2. Aufl. 2011, S.854-864
- 63 **Tadic A, Lieb K**. Schneller aus der Depression: Die Early Medication Change (EMC)-Studie. Neuro aktuell. 2011; (1): 27-28
- 64 **Tadic A, Wagner S**, Gorbulev S, **Dahmen N, Hiemke C**, Braus DF, **Lieb K**. Peripheral blood and neuropsychological markers for the onset of action of

antidepressant drugs in patients with Major Depressive Disorder. BMC PSYCHIATRY. 2011; 11: -

- 65 **Tadic A, Wagner S, Schlicht KF, Peetz D, Borysenko L, Dreimüller N, Hiemke C, Lieb K.** The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: A pilot study. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY. 2011; 35 (2): 415-420
- 66 Teipel SJ, Reuter S, Stieltjes B, Acosta-Cabronero J, Ernemann U, **Fellgiebel A**, Filippi M, Frisoni G, Hentschel F, Jessen F, Kloppel S, Meindl T, Pouwels PJW, Hauenstein KH, Hampel H. Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. PSYCHIATRY RESEARCH-NEUROIMAGING. 2011; 194 (3): 363-371
- 67 **Tüscher O**, Protopopescu X, Pan H, Cloitre M, Butler T, Goldstein M, Root JC, Engeli A, Furman D, Silverman M, Yang YH, Gorman J, LeDoux J, Silbersweig D, Stern E. Differential activity of subgenual cingulate and brainstem in panic disorder and PTSD. JOURNAL OF ANXIETY DISORDERS. 2011; 25 (2): 251-257
- 68 **Tüscher O**, Zimmerman DJ, Silbersweig DA. Functional imaging of other anxiety disorders. Beitrag in: Understanding neuropsychiatric disorders: Insights from Neuroimaging. Herausgeber: Shenton ME, Turetsky BI, Cambridge University Press Cambridge, 2011, S.288-294
- 69 Veselinović T, Schorn H, Vernaleken I, Schiffl K, **Hiemke C**, Zernig G, Gur R, Gründer G. Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. Psychopharmacology (Berl). 2011; 218(4): 733-748
- 70 Voigt-Radloff S, Graff M, Leonhart R, Schornstein K, Jessen F, Bohlken J, Metz B, **Fellgiebel A**, Dodel R, Eschweiler G, Vernooij-Dassen M, Olde Rikkert M, Hüll M. A multicentre RCT on community occupational therapy in Alzheimer's disease: 10 sessions are not better than one consultation. BMJ Open. 2011; 1(1): 1-11
- 71 Vollstädt-Klein S, Kobiella A, Bühler M, Graf C, **Fehr C**, Mann K, Smolka MN. Severity of dependence modulates smokers' neuronal cue reactivity and cigarette craving elicited by tobacco advertisement. ADDICTION BIOLOGY. 2011; 16 (1): 166-175
- 72 Vossel S, Warbrick T, **Mobascher A**, Winterer G, Fink GR. Spatial and sustained attention in relation to smoking status: behavioural performance and brain activation patterns. JOURNAL OF PSYCHOPHARMACOLOGY. 2011; 25(11): 1485-1495
- 73 **Wagner S, Helmreich I, Dahmen N, Lieb K, Tadic A.** Reliability of Three Alternate Forms of the Trail Making Tests A and B. ARCHIVES OF CLINICAL NEUROPSYCHOLOGY. 2011; 26 (4): 314-321

- 74 **Wagner S, Helmreich I, Lieb K, Tadic A.** Standardized Rater Training for the Hamilton Depression Rating Scale (HAMD(17)) and the Inventory of Depressive Symptoms (IDSC30). *PSYCHOPATHOLOGY*. 2011; 44 (1): 68-70
- 75 Warbrick T, **Mobascher A**, Brinkmeyer J, Musso F, Stoecker T, Shah NJ, Vossel S, Winterer G. Direction and magnitude of nicotine effects on the fMRI BOLD response are related to nicotine effects on behavioral performance. *PSYCHOPHARMACOLOGY*. 2011; 215 (2): 333-344
- 76 Weih M, Bachmeier C, Degirmenci U, Sojer R, Kreil S, Thürauf N, Prokosch HU, **Hiemke C**, Kornhuber J. Datenbankgestützte Prüfung von möglichen Psychopharmakainteraktionen nach Entlassung aus stationärem Aufenthalt. Assessment of Possible Drug-Drug Interactions in Psychopharmacotherapy after Hospital Discharge using an Interactive Database. *FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE*. 2011; 79 (2): 92-96
- 77 **Wiesner A, Lieb K.** Interessenkonflikte durch Arzt-Industrie-Kontakte in Praxis und Klinik und Vorschläge zu deren Reduzierung. Beitrag in: Interessenkonflikte in der Medizin. Hintergründe und Lösungsmöglichkeiten. Herausgeber: Lieb K, Klemperer D, Ludwig WD, Springer 2011, S.162-173
- 78 **Yakushev I, Gerhard A, Müller MJ, Lorscheider M**, Buchholz HG, **Schermuly I**, Weibrich C, Hammers A, Stoeter P, Schreckenberger M, **Fellgiebel A.** Relationships between hippocampal microstructure, metabolism, and function in early Alzheimer's disease. *BRAIN STRUCTURE & FUNCTION*. 2011; 216(3): 219-226
- 79 **Yakushev I**, Schreckenberger M, **Müller MJ, Schermuly I**, Cumming P, Stoeter P, **Gerhard A, Fellgiebel A.** Functional implications of hippocampal degeneration in early Alzheimer's disease: a combined DTI and PET study. *EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING*. 2011; 38 (12): 2219-2227
- 80 Yu ZH, Kastenmüller G, He Y, Belcredi P, Möller G, Prehn C, Mendes J, Wahl S, Roemisch-Margl W, Ceglarek U, Polonikov A, **Dahmen N**, Prokisch H, Xie L, Li YX, Wichmann HE, Peters A, Kronenberg F, Suhre K, Adamski J, Illig T, Wang-Sattler R. Differences between Human Plasma and Serum Metabolite Profiles. *PLOS ONE*. 2011; 6(7): 1-6, e21230